Fibrosis first symposium

Downloads and Links

Synopsis
Fibrosis disease is the result of a dysregulated wound healing process and is responsible for considerable patient mortality affecting multiple organs in diseases such as idiopathic pulmonary fibrosis (IPF), diabetic nephropathy, steatohepatitis and systemic sclerosis. Fibrosis disease pathology is often complex and this inaugural symposium on fibrosis will provide mechanistic insight and progress in medicinal chemistry and drug discovery from experts across the world.

Programme

09.00
Registration and refreshments

Session chair: Luis Castro, UCB
09.30
Welcome and opening remarks
Luis Castro, UCB
09.35
The common denominator of chronic disease - Fibrosis
Robert M Strieter, Novartis
10.20
Out of the frying-pan PI3K and into....? Generation of a robust pathway toolbox to investigate the anti-fibrotic behaviour of GSK2126458A
Simon Peace, GlaxoSmithKline
10.50
Refreshments

Session Chair: Richard Hatley, GlaxoSmithKline
11.20
Design of mechanism-based amine oxidase inhibitors for the treatment of fibrosis
Jonathan Foot, Pharmaxis
11.50
Tissue transglutaminase - a credible therapeutic target in the treatment of fibrotic disease due to its multifunctional roles?
Martin Griffin, Aston University

12.20
Flash presentations
Structure-based design, synthesis, and biological evaluation of novel autotaxin inhibitors
Lisa Miller, University of Strathclyde
12.23
Toward novel treatment units in fibrosis
Frances Potjewyd, University of Strathclyde
12.26 Structure activity relationship of PF-8380 and development of a novel chemotype towards autotaxin inhibition
Emma Duffy, University of Strathclyde
12.30
Lunch

Session chair: Tim Johnson, UCB
13.30
Structure activity relationships of αv integrin antagonists - industrial medicinal chemistry with 4th year MSci undergraduates
Simon Macdonald, GlaxoSmithKline, and Thomas McInally, University of Nottingham
14.00
Harnessing our understanding of scleroderma (systemic sclerosis) to develop and validate innovative anti-fibrotic therapies (advancing drug discovery towards patient care)
David Abraham, University College London
14.30
Discovery and quantitation of novel liver fibrosis biomarkers: towards the first antibody-free biomarker assay for liver fibrosis
Bevin Gangadharan, University of Oxford
14.40
Refreshments
15.10
Role of NOX enzymes in fibrotic diseases: development of a 1st in class NOX1/4 inhibitor GKT137831
Cédric Szyndralewiez, Genkyotex
15.40
Does CB2 agonism protect from inflammation related organ damage and fibrosis?
Uwe Grether, F Hoffmann-La Roche
16.10
IPF active macrocycles identified from phenotypic screening
Gordon Saxty, Fidelta
16.50
Closing remarks
Luis Castro, UCB
17.00
Technical programme ends
Drinks reception
18.00 Close

Call for posters

Posters were invited for display throughout the meeting. The closing date was Friday, 9th October.

Registration

Registration is closed.

Fees until 6th August
£100    RSC or SCI member
£130    Non-member
£50    RSC or SCI student* member
£65    Student* non-member

Fees from 7th August to 7th October
£120    RSC or SCI member
£150    Non-member
£60    RSC or SCI student* member
£75    Student* non-member
£30    Late payment fee for payments received from 8th October onwards

* Student is undergraduate or post-graduate, not post-doc

Bursaries and Students

Discounted rates were offered to RSC and SCI student members, and some bursaries were available from the RSC and the SCI, maximum value of £250 each.

Venue and Travel

Address: UCB, 208 Bath Road, Slough SL1 3WE, UK.

Travel: UCB is a 5-minute taxi journey from Slough railway station, 30 minutes from Heathrow airport by car, and easily accessible by car from the M25, M4 and M40. Travel information may be found here.

Accommodation

A number of rooms were held at the nearby 4* Copthorne Slough Windsor Hotel for the night of Monday, 9th November. The charge was £119 for a standard double room for single occupancy, and included breakfast, wi-fi, and VAT. Any unbooked rooms have now been released.

Address: Lower Cippenham Lane, Slough SL1 2YE, telephone 01753 516222.
The distance from UCB is two minutes by car (0.9 miles), or shorter distance on foot.

Exhibition Opportunities

Very limited exhibition stand space was available, priced up as below:

£500 Exhibition stand space with one full delegate
£500 Exhibition stand space with two trade stand staff

(no access to technical sessions)

Each exhibitor could display a maximum of two pull-up roller panels, each measuring no more than 1 metre wide.

Sponsors

We are grateful to our sponsors:

Organising Committee

Richard Hatley (co-chairman), GlaxoSmithKline
Simon Peace (co-chairman), GlaxoSmithKline
Mark Healy, Novartis
Fabien Lecomte, UCB Pharma
Mihiro Sunose, Sygnature Discovery

Registration is closed